KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) EPS (Basic): 2017-2025

Historic EPS (Basic) for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Sep 2025 value amounting to $0.01.

  • Amneal Pharmaceuticals' EPS (Basic) fell 73.67% to $0.01 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.02, marking a year-over-year increase of 102.43%. This contributed to the annual value of -$0.38 for FY2024, which is 20.83% up from last year.
  • As of Q3 2025, Amneal Pharmaceuticals' EPS (Basic) stood at $0.01, which was down 85.71% from $0.07 recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' EPS (Basic) ranged from a high of $0.10 in Q2 2021 and a low of -$0.80 during Q2 2022.
  • For the 3-year period, Amneal Pharmaceuticals' EPS (Basic) averaged around -$0.06, with its median value being $0.02 (2024).
  • Within the past 5 years, the most significant YoY rise in Amneal Pharmaceuticals' EPS (Basic) was 400.00% (2023), while the steepest drop was 1,833.33% (2023).
  • Amneal Pharmaceuticals' EPS (Basic) (Quarterly) stood at -$0.04 in 2021, then climbed by 25.00% to -$0.03 in 2022, then plummeted by 1,833.33% to -$0.58 in 2023, then skyrocketed by 82.76% to -$0.10 in 2024, then plummeted by 73.67% to $0.01 in 2025.
  • Its EPS (Basic) was $0.01 in Q3 2025, compared to $0.07 in Q2 2025 and $0.04 in Q1 2025.